Atossa Therapeutics Optimizes EVANGELINE Breast Cancer Trial for 2026 Regulatory Activities Atossa Therapeutics has revised its EVANGELINE trial design to improve efficiency and focus on 2026 NDA-enabling efforts, reducing costs and expediting study outcomes.

Atossa Therapeutics Optimizes EVANGELINE Breast Cancer Trial for 2026 Regulatory Activities #United_States #Seattle #Atossa_Therapeutics #Z-Endoxifen #EVANGELINE_Study